PL2785359T3 - Mezenchymalne komórki zrębowe i związane z nimi zastosowania - Google Patents

Mezenchymalne komórki zrębowe i związane z nimi zastosowania

Info

Publication number
PL2785359T3
PL2785359T3 PL12854438T PL12854438T PL2785359T3 PL 2785359 T3 PL2785359 T3 PL 2785359T3 PL 12854438 T PL12854438 T PL 12854438T PL 12854438 T PL12854438 T PL 12854438T PL 2785359 T3 PL2785359 T3 PL 2785359T3
Authority
PL
Poland
Prior art keywords
mezenchymal
related applications
rigid cells
rigid
cells
Prior art date
Application number
PL12854438T
Other languages
English (en)
Inventor
Robert Lanza
Erin Anne Kimbrel
Jianlin Chu
Nicholas Arthur Kouris
Original Assignee
Astellas Institute For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48536141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2785359(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Institute For Regenerative Medicine filed Critical Astellas Institute For Regenerative Medicine
Publication of PL2785359T3 publication Critical patent/PL2785359T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/141—Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/08—Devices or methods enabling eye-patients to replace direct visual perception by another kind of perception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/54—Interprogram communication
    • G06F9/542—Event management; Broadcasting; Multicasting; Notifications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2218/00—Aspects of pattern recognition specially adapted for signal processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
PL12854438T 2011-11-30 2012-11-30 Mezenchymalne komórki zrębowe i związane z nimi zastosowania PL2785359T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565358P 2011-11-30 2011-11-30
EP12854438.4A EP2785359B1 (en) 2011-11-30 2012-11-30 Mesenchymal stromal cells and uses related thereto
PCT/US2012/067464 WO2013082543A1 (en) 2011-11-30 2012-11-30 Mesenchymal stromal cells and uses related thereto

Publications (1)

Publication Number Publication Date
PL2785359T3 true PL2785359T3 (pl) 2018-12-31

Family

ID=48536141

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12854438T PL2785359T3 (pl) 2011-11-30 2012-11-30 Mezenchymalne komórki zrębowe i związane z nimi zastosowania

Country Status (19)

Country Link
US (5) US8962321B2 (pl)
EP (2) EP3449929B1 (pl)
JP (5) JP2015500810A (pl)
KR (4) KR102246369B1 (pl)
CN (2) CN108478599B (pl)
AU (4) AU2012345630A1 (pl)
CA (1) CA2857545A1 (pl)
CY (1) CY1122275T1 (pl)
DK (1) DK2785359T3 (pl)
ES (1) ES2690212T3 (pl)
HR (1) HRP20181515T1 (pl)
HU (1) HUE040566T2 (pl)
LT (1) LT2785359T (pl)
PL (1) PL2785359T3 (pl)
PT (1) PT2785359T (pl)
RS (1) RS57886B1 (pl)
SI (1) SI2785359T1 (pl)
TW (4) TWI698242B (pl)
WO (1) WO2013082543A1 (pl)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
JP5748654B2 (ja) 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
KR102246369B1 (ko) 2011-11-30 2021-04-29 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
WO2014011881A2 (en) 2012-07-11 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US9745551B2 (en) 2012-07-12 2017-08-29 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
DK2840132T3 (en) 2013-08-22 2017-02-20 Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts Universitätsmedizin Method of Manufacturing Constructed Heart Muscle (EHM)
CA3239291A1 (en) * 2013-11-18 2015-05-21 Nick Giannoukakis Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
US10624930B2 (en) * 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
CN104232573B (zh) * 2014-09-11 2017-01-11 安沂华 一种生长培养基及其用途和培养脐带间充质干细胞的方法
US20160095885A1 (en) * 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104531613B (zh) * 2014-11-17 2017-12-19 中国农业科学院北京畜牧兽医研究所 Wip1敲除在促进小鼠骨髓间充质干细胞迁移中的应用
EP3236977B1 (en) * 2014-12-23 2023-06-21 Mesoblast International Sàrl Method for treating heart failure
ES2980659T3 (es) 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
CN108368479A (zh) * 2015-09-29 2018-08-03 细胞结构公司 细胞效能分析
WO2017060240A1 (en) * 2015-10-05 2017-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method and culture medium for ex vivo culturing of epidermis-derived stem cells
CN108601799A (zh) * 2015-11-04 2018-09-28 德克萨斯大学系统董事会 从年长细胞群中富集和扩增高潜能人间充质干细胞
EP3381458B1 (en) * 2015-11-24 2023-06-07 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
CN105326864A (zh) * 2015-11-30 2016-02-17 奥思达干细胞有限公司 一种治疗系统性红斑狼疮的干细胞制剂及其制备方法
WO2017143219A2 (en) * 2016-02-18 2017-08-24 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by t regulatory cells
CN105671000A (zh) * 2016-03-02 2016-06-15 深圳爱生再生医学科技有限公司 重组间充质干细胞及其制备方法和应用
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR20190038833A (ko) * 2016-07-11 2019-04-09 보누스 테라퓨틱스 리미티드 조직 재생용 세포 조성물
CN106265899A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种组合物及其在制备改善慢性鼻炎的产品中的应用
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN106520686A (zh) * 2016-10-11 2017-03-22 海南博鳌龄迈迪精准医学研究院有限公司 脂肪间充质干细胞的培养方法
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
KR101971322B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
MX2019005127A (es) * 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.
CN106581760A (zh) * 2016-11-08 2017-04-26 华南生物医药研究院 增强细胞活性的特殊处理方法
CN106619721A (zh) * 2016-11-08 2017-05-10 中国人民解放军军事医学科学院野战输血研究所 一种增强细胞活性的新方法
CN106563161A (zh) * 2016-11-08 2017-04-19 华南生物医药研究院 可用于美容的新型药物组合剂
KR102390909B1 (ko) * 2016-12-19 2022-04-26 주식회사 파이안바이오테크놀로지 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703058D0 (en) * 2017-02-24 2017-04-12 Ucl Business Plc Biomarkers
CN110494556B (zh) * 2017-04-03 2024-04-30 株式会社钟化 包含间充质系干细胞的细胞群、其制造方法、以及医药组合物
EP3739038A4 (en) * 2017-05-12 2021-03-31 National University Corporation Tokyo Medical and Dental University Method for purifying mesenchymal stem cells to improve transplantation efficiency
US20200206272A1 (en) * 2017-06-19 2020-07-02 National University Corporation Hokkaido University Treatment agent for epidermolysis bullosa
CN107490701B (zh) * 2017-08-17 2021-09-14 上海集技生物技术有限公司 一种基于局部照射的全身性骨损伤模型的建立及病理机制分析的方法
CN107714726A (zh) 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
CN109069543B (zh) * 2017-10-16 2020-02-18 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
CA3081768A1 (en) * 2017-11-06 2019-05-09 King's College London Therapeutic substances, their preparation and diagnostic procedure
KR102095628B1 (ko) * 2018-01-05 2020-04-01 재단법인 아산사회복지재단 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물
EP3752598B1 (en) * 2018-02-16 2022-11-02 NextCell Pharma AB Allogeneic composition
US12390492B2 (en) 2018-03-07 2025-08-19 Aya BARZELAY Compositions and methods for treating age-related macular degeneration
MA52883A (fr) * 2018-06-15 2021-05-26 Prieto Manuel Hermida Composition pharmaceutique pour dermatologie et ses utilisations
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
CN109082409A (zh) * 2018-09-14 2018-12-25 四川新生命干细胞科技股份有限公司 一种组织修复能力强的脂肪干细胞分离培养及筛选方法
CN109182262A (zh) * 2018-09-25 2019-01-11 深圳市五零生命科技有限公司 一种间充质干细胞无血清培养基
AU2019387218A1 (en) * 2018-11-26 2021-06-03 Massachusetts Institute Of Technology Compositions and methods for immune tolerance
CN109342739A (zh) * 2018-11-27 2019-02-15 上海科医联创生物科技有限公司 一种鉴定间充质干细胞纯度的方法
CN109609584A (zh) * 2018-12-10 2019-04-12 天津长和生物技术有限公司 间充质干细胞免疫调节能力的检测方法
SG11202108114YA (en) * 2019-02-27 2021-08-30 Tigenix S A U Improved stem cell populations for allogeneic therapy
MX2021010739A (es) * 2019-03-12 2021-12-15 Boehringer Ingelheim Veterinary Medicine Belgium Celulas madre mesenquimales inmunomoduladoras.
WO2020184729A1 (ja) 2019-03-14 2020-09-17 北海道公立大学法人札幌医科大学 筋萎縮性側索硬化症の治療用医薬組成物
EP4004191A4 (en) 2019-07-26 2022-10-12 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same
CN110305839A (zh) * 2019-08-02 2019-10-08 陕西佰傲干细胞再生医学有限公司 间充质干细胞无血清培养基
JP2022545737A (ja) 2019-08-28 2022-10-28 アステラス インスティテュート フォー リジェネラティブ メディシン 血管疾患を処置する組成物および方法
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
CN110564674B (zh) * 2019-09-29 2021-05-11 广东工业大学 一种干细胞铺底工作液及其应用
WO2021072595A1 (zh) * 2019-10-14 2021-04-22 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在治疗听力障碍上的医药用途
RU2740152C1 (ru) * 2020-01-09 2021-01-13 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН) Способ активации пролиферативного ответа фибробластоподобных клеток стромально-васкулярной фракции жировой ткани
WO2021169017A1 (zh) * 2020-02-25 2021-09-02 上海大学 间充质干细胞在治疗重症covid19肺炎中的用途
CN115297877A (zh) * 2020-04-13 2022-11-04 国立大学法人东海国立大学机构 肾脏中cd25阳性调节性t细胞增加剂
AU2021264523A1 (en) * 2020-04-28 2022-12-08 Factor Bioscience Inc. Mesenchymal stem cell therapies
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111518761B (zh) * 2020-05-25 2022-04-29 青岛瑞思德生物科技有限公司 一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法
WO2022004938A1 (ko) * 2020-06-30 2022-01-06 주식회사 미래셀바이오 유사 중간엽 줄기세포의 제조방법
EP3945133A1 (en) * 2020-07-29 2022-02-02 Georg-August-Universität Göttingen Mass production of human pluripotent stem cell derived cardiac stromal cell
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US20230405051A1 (en) * 2020-10-22 2023-12-21 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for prevention or treatment of rheumatoid arthritis, comprising, as active ingredient, stem cells having expression of specific genes increased or decreased therein
US20240366676A1 (en) * 2021-05-07 2024-11-07 Sungkwang Medical Foundation Mesenchymal stem cells having enhanced osteogenic differentiation capacity, and use thereof
WO2023280835A1 (en) * 2021-07-08 2023-01-12 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of chronic gingivostomatitis
CN113717972B (zh) * 2021-08-16 2022-07-01 南通市肿瘤医院 MYADM靶向的siRNA及其应用
CA3234969A1 (en) * 2021-10-12 2023-04-20 Makoto Funaki Anti-aging composition using mesenchymal stem cells and methods thereof
CA3243344A1 (en) * 2022-02-07 2023-08-10 Smartcella Solutions Ab METHODS AND COMPOSITIONS FOR GENERATING HUMAN INDUCED MESENCHYMATOUS STEM CELLS
CN114984051A (zh) * 2022-06-27 2022-09-02 广州惠善医疗技术有限公司 间充质干细胞在制备治疗炎症及免疫相关疾病的药物中的应用
WO2024007038A2 (en) * 2022-07-01 2024-01-04 Northwestern University Compositions and methods for the treatment of intestinal inflammation
JP2025527112A (ja) 2022-07-18 2025-08-20 アステラス インスティテュート フォー リジェネレイティブ メディシン 脳傷害を処置する方法
CN115305234B (zh) * 2022-09-28 2023-01-17 呈诺再生医学科技(北京)有限公司 一种制备间充质干细胞的方法、间充质干细胞和应用
WO2024158058A1 (ja) * 2023-01-27 2024-08-02 株式会社Rainbow 自動培養装置における細胞増殖制御方法
TW202434721A (zh) * 2023-02-14 2024-09-01 國立大學法人山口大學 細胞群、三維細胞培養體、醫藥組成物、胞泌體及製作此細胞群的方法
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法
CN117210528B (zh) * 2023-09-12 2024-08-20 长沙干细胞与再生医学工业技术研究院有限公司 一种综合评估间充质干细胞免疫调控能力的方法
WO2025084581A1 (ko) * 2023-10-18 2025-04-24 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포를 포함하는 복막 섬유증의 개선, 예방 또는 치료용 조성물

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6416581A (en) * 1987-07-09 1989-01-20 Rikagaku Kenkyusho Frozen animal cell and production thereof
US5128259A (en) 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
EP0739412B1 (en) 1993-12-23 2002-02-27 Infigen, Inc. ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
WO1998033891A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
WO1998053048A1 (en) 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6429012B1 (en) 1997-10-06 2002-08-06 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
AU4336599A (en) 1998-06-08 1999-12-30 Osiris Therapeutics, Inc. (in vitro) maintenance of hematopoietic stem cells
WO1999067360A2 (en) 1998-06-25 1999-12-29 Hemosol Inc. Media and methods for expansion of erythroid stem cells for the production of hemoglobin
WO2000011139A1 (en) 1998-08-24 2000-03-02 T.Breeders, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
WO2001029206A1 (en) 1999-10-15 2001-04-26 Advanced Cell Technology, Inc. Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells
WO2001036589A2 (en) 1999-11-17 2001-05-25 University Of Rochester Human ex vivo immune system
JP2003533976A (ja) 2000-01-07 2003-11-18 オレゴン ヘルス アンド サイエンス ユニバーシティ 胚分割による霊長類子孫のクローン性増殖
EP1248834A4 (en) 2000-01-21 2004-03-17 Univ Johns Hopkins CELLS FROM HUMAN EMBRYOID BODIES
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
CA2417356A1 (en) 2000-08-01 2002-02-07 Yissum Research Development Company Directed differentiation of embryonic cells
MXPA03002414A (es) 2000-09-18 2004-07-08 Organogenesis Inc Protesis con injerto de hoja plana tratada por bioingenieria y su uso.
AU2002335610C1 (en) 2001-01-29 2008-09-25 Hemogenix, Inc. High-throughput stem cell assay of hematopoietic stem and progenitor cell proliferation
WO2002078449A2 (en) 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
KR20020083634A (ko) 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
CA2447015A1 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
WO2003038072A1 (en) 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
MXPA04004067A (es) 2001-11-02 2004-07-08 Wisconsin Alumni Res Found Celulas endoteliales derivadas de embriocitos de primate.
JP4330995B2 (ja) * 2001-11-15 2009-09-16 チルドレンズ メディカル センター コーポレーション 絨毛膜絨毛、羊水、および胎盤からの胎児性幹細胞を単離、増殖、および分化させる方法、ならびにその治療的使用方法
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20030153082A1 (en) 2001-12-07 2003-08-14 The John P. Robarts Research Institute Hematopoietic cells from human embryonic stem cells
JP2005528362A (ja) * 2002-03-21 2005-09-22 ユニヴァーシティ オヴ フロリダ 血管新生の調節法
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
US20060165666A1 (en) 2002-07-12 2006-07-27 Lim Sai K Hemangioblast progenitor cells
AR047712A1 (es) 2002-09-07 2006-02-15 Royal Veterinary College Metodo de tratamiento de una lesion de tejido esqueletico blando natural administrando una composicion de celulas madre mesenquimatosas
WO2004029231A1 (en) 2002-09-26 2004-04-08 Institut National De La Sante Et De La Recherche Medicale Compositions and methods for amplification of human stem cells
AU2003273332A1 (en) 2002-09-26 2004-04-19 Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
US20050054096A1 (en) 2002-11-06 2005-03-10 Piniella Carlos J. Pluripotent cells from monocytes, and methods of making and using pluripotent cells
US20040156878A1 (en) 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
JP2006525006A (ja) 2003-05-08 2006-11-09 セルアーティス アーベー 閉塞ストローガラス化方法を利用するヒト胚盤胞由来幹細胞の低温保存法
US20040229350A1 (en) 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
CA2550326A1 (en) 2003-12-19 2005-07-14 Viacell, Inc. Use of human cord blood-derived pluripotent cells for the treatment of disease
CN1286970C (zh) 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
EP1711594A4 (en) 2004-01-02 2007-07-11 Advanced Cell Tech Inc NEW CULTURAL SYSTEMS FOR EX-VIVO DEVELOPMENT
KR100535326B1 (ko) 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
BRPI0507074A (pt) 2004-01-23 2007-06-19 Advanced Cell Tech Inc modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina
KR20060114366A (ko) 2004-02-09 2006-11-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 클론원성 내피 전구 세포의 분리, 팽창 및 용도
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20050221482A1 (en) 2004-03-31 2005-10-06 Burt Richard K Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
KR20070015588A (ko) 2004-05-07 2007-02-05 위스콘신 얼럼나이 리서어치 화운데이션 배아 줄기 세포로부터 중간엽 줄기 세포를 형성하는 방법
CA2566549C (en) * 2004-05-12 2014-01-14 The Walter And Eliza Hall Institute Of Medical Research A method for isolating mammary stem cells
US8206979B2 (en) 2004-06-04 2012-06-26 Universite Pierre et Marie Curie — Paris VI Method for producing red blood cells
WO2006001120A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
CA2866468C (en) 2004-09-24 2019-09-03 Mesoblast, Inc. Generating multipotential expanded mesenchymal precursor cell progeny (memp) from mesenchymal progenitor cells (mpc) and stimulation factor
JP2008518603A (ja) 2004-11-01 2008-06-05 ウイスコンシン アラムニ リサーチ ファンデーション 幹細胞由来の血小板
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US20080166751A1 (en) 2005-02-23 2008-07-10 Takayuki Asahara Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells
EP1860180A4 (en) 2005-02-23 2009-03-11 Found Biomedical Res & Innov METHOD FOR THE AMPLIFICATION OF AN ENDOTHEL PREPARATION CELL IN VITRO
JP2006230316A (ja) * 2005-02-25 2006-09-07 Japan Health Science Foundation 瘢痕のない創傷治癒能を有する細胞およびその調製方法
AU2006224313B2 (en) 2005-03-17 2011-08-11 Ucl Biomedica Plc Method for actvating Natural Killer cells by tumor cell preparation in vitro
CN101155914B (zh) 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
EP1891438A4 (en) 2005-05-27 2008-12-10 Advanced Cell Tech Inc METHOD OF IDENTIFYING LIGANDS FOR STEM CELLS AND CELLS DERIVED FROM THESE
EP1885845A2 (en) 2005-06-01 2008-02-13 Wisconsin Alumni Research Foundation Method of forming dendritic cells from embryonic stem cells
WO2007005595A1 (en) 2005-07-05 2007-01-11 The New England Medical Center Hospitals, Inc. Pregnancy-associated progenitor cells
EP2302034B1 (en) 2005-08-03 2020-10-14 Astellas Institute for Regenerative Medicine Improved methods of reprogramming animal somatic cells
EP1909565A2 (en) 2005-08-03 2008-04-16 Interface Multigrad Technology (IMT) Ltd. Somatic cells for use in cell therapy
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
WO2007032634A1 (en) 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University A method for production of mature natural killer cell
JP2007089432A (ja) 2005-09-27 2007-04-12 Reprocell Inc 幹細胞由来血小板産生増加法
SI1941027T1 (sl) 2005-09-28 2014-11-28 Ipd-Theapeutics B.V. Postopki in sredstva za proliferacijo zarodnih celic in kasnejšo generacijo in ekspanzijo progenitorskih celic, kot tudi izdelava efektor celic kot kliničnih zdravil
WO2007047894A2 (en) 2005-10-20 2007-04-26 Advanced Cell Technology, Inc. Totipotent, nearly totipotent or pluripotent mammalian cells homozygous or hemizygous for one or more histocompatibility antigen genes
WO2007050043A2 (en) 2005-10-24 2007-05-03 Agency For Science, Technology And Research Methods of specifying mesodermal, endodermal and mesoendodermal cell fates
WO2007062198A1 (en) 2005-11-21 2007-05-31 Advanced Cell Technology, Inc. Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
CA2641967C (en) 2006-02-09 2019-03-19 Wisconsin Alumni Research Foundation Erythroid cells producing adult-type .beta.-hemoglobin generated from human embryonic stem cells
EP1991664B1 (en) * 2006-02-16 2018-03-28 Ospedale San Raffaele S.r.l. Skeletal muscle periangioblasts and cardiac mesangioblasts, method for isolation and uses thereof
WO2007099337A1 (en) 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
CN101045915A (zh) 2006-03-29 2007-10-03 旭日干 一种卵母细胞生发泡移植技术
CN101045914A (zh) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
KR102651433B1 (ko) * 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
AU2013201444B2 (en) 2006-04-14 2015-01-22 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
NZ572842A (en) 2006-04-14 2012-01-12 Advanced Cell Tech Inc Hemangio-colony forming cells
KR100791487B1 (ko) 2006-05-29 2008-01-03 연세대학교 산학협력단 제대혈로부터 간엽줄기세포의 분리 및 배양 방법
US20070298496A1 (en) 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
EP2076116A4 (en) 2006-10-11 2010-04-07 Gen Hospital Corp COMPOSITIONS, METHODS, AND DEVICES FOR TREATING HEPATIC DISEASES
US20080108044A1 (en) 2006-11-08 2008-05-08 Deepika Rajesh In vitro differentiation of hematopoietic cells from primate embryonic stem cells
US20110151554A1 (en) 2006-11-09 2011-06-23 Akira Yuo Method for culturing and subculturing primate embryonic stem cell, as well as method for inducing differentiation thereof
DE102006054041B3 (de) 2006-11-16 2008-05-08 Pierburg Gmbh Regelvorrichtung für eine Verbrennungskraftmaschine
JP2010518857A (ja) 2007-02-23 2010-06-03 アドバンスド セル テクノロジー， インコーポレイテッド 分化した細胞の再プログラムおよび再プログラムされた細胞からの動物および胚幹細胞の生成のための高能率的な方法
BRPI0811906A2 (pt) 2007-05-24 2014-11-18 Apceth Gmbh & Co Kg Composições e métodos relacionados a célula-tronco cd34
WO2008151386A1 (en) 2007-06-15 2008-12-18 Australian Stem Cell Centre Ltd Megakaryocyte differentiation
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9095562B2 (en) 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
EP3424514B1 (en) 2007-08-06 2022-05-11 Mesoblast, Inc. Tnap+ mesenchymal precursor cells for use in treating connective tissue diseases
KR101039235B1 (ko) * 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
US20110236971A2 (en) 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
RU2536242C2 (ru) 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
IL292561A (en) 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
WO2009052389A1 (en) 2007-10-19 2009-04-23 Baylor College Of Medicine Hematopoietic fingerprints: methods of use
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
US10046011B2 (en) 2008-01-31 2018-08-14 Rutgers, The State University Of New Jersey Compositions for inducing or suppressing an immune response
US8685728B2 (en) 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
US9415036B2 (en) 2008-02-15 2016-08-16 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
WO2009104825A1 (en) * 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
JP5748654B2 (ja) 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
EP2712921B1 (en) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
BE1018748A3 (fr) 2008-05-07 2011-08-02 Bone Therapeutics Sa Nouvelles cellules souches mesenchymateuses et cellules osteogeniques .
EP2321408A4 (en) * 2008-08-04 2013-04-17 Allocure Inc MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE
CA2735800C (en) 2008-09-03 2018-05-01 Angioblast Systems, Inc. Expansion of haemopoietic precursors
FR2938947B1 (fr) 2008-11-25 2012-08-17 A Volute Procede de traitement du signal, notamment audionumerique.
EP2221362A1 (en) 2009-02-19 2010-08-25 Naturin GmbH & Co Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
CN102439136A (zh) 2009-03-26 2012-05-02 加州大学校董 产生用于疾病修饰的抑制性rna的间充质干细胞
JP2010252778A (ja) * 2009-04-02 2010-11-11 Shizui Bank Kk 歯髄由来間葉系幹細胞の分離方法及び分離した幹細胞並びにそれらを用いた肝細胞系譜への分化
CA2767300C (en) 2009-07-09 2020-01-07 Cellerix Sa Methods and compositions for use in cellular therapies
EP2485741A4 (en) 2009-10-06 2013-07-24 Cohen Mcniece Foundation PREPARATION AND USE OF STROMAL CELLS FOR THE TREATMENT OF CARDIAC DISORDERS
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
US20120269779A1 (en) * 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US8900860B2 (en) * 2009-11-30 2014-12-02 National Yang-Ming University Method for expanding mesenchymal stem cells in low-density and hypoxic culture
US9988603B2 (en) 2009-12-04 2018-06-05 Stem Cell & Regenerative Medicine International Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
CA3095576A1 (en) 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
AU2011213081A1 (en) 2010-02-02 2012-08-23 University Of Rochester Methods of isolating and culturing mesenchymal stem cells
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
CA2792802C (en) 2010-03-10 2017-10-31 Two Cells Co., Ltd. Cell preparation containing mesenchymal stem cells, and method for producing same
WO2011124741A1 (es) 2010-04-08 2011-10-13 Fundación Progreso Y Salud Uso de un medio de cultivo condicionado por células madre mesenquimales para la diferenciación de células madre pluripotentes humanas
KR101330327B1 (ko) 2010-05-07 2013-11-14 한국생명공학연구원 줄기세포로부터 생성된 배아체를 대량 증식 및 유지하는 방법
WO2012026712A2 (ko) 2010-08-23 2012-03-01 주식회사 강스템홀딩스 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
US20120087933A1 (en) * 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
KR102246369B1 (ko) 2011-11-30 2021-04-29 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
KR101477016B1 (ko) 2012-01-19 2014-12-29 (주)차바이오텍 인간 배아줄기세포 유래 혈관주위 전구세포의 제조방법 및 이를 포함하는 세포치료 조성물
US9745551B2 (en) 2012-07-12 2017-08-29 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA2895148C (en) 2012-12-14 2023-02-28 Yufang Shi Methods modulating immunoregulatory effect of stem cells
US20160008401A1 (en) 2013-03-01 2016-01-14 Apceth Gmbh & Co. Kg Protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells
KR101669124B1 (ko) 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
EP3052943B1 (en) 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
SG11201606832YA (en) 2014-02-18 2016-09-29 Massachusetts Inst Technology Biophysically sorted osteoprogenitors from culture expanded bone marrow derived mesenchymal stromal cells (mscs)
US10624930B2 (en) 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders
JP6459257B2 (ja) 2014-07-08 2019-01-30 富士ゼロックス株式会社 画像形成装置
WO2016018761A1 (en) 2014-07-28 2016-02-04 The Texas A&M University System Mesenchymal stem cells expressing biomarkers that predict the effectiveness of the mesenchymal stem cells for treating diseases and disorders
JP6998768B2 (ja) 2015-08-28 2022-02-10 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞及びその調製方法、ｒｏｒ１陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる疾患の予防又は治療方法
CN109312302A (zh) 2015-10-27 2019-02-05 株式会社钟化 包含间充质系干细胞的细胞群的制造方法、间充质系干细胞、细胞群、以及医药组合物
KR102676761B1 (ko) 2015-12-03 2024-06-18 다카라 바이오 가부시키가이샤 중간엽 줄기세포의 제조방법
JP7048977B2 (ja) 2016-03-16 2022-04-06 サイナータ セラピューティクス リミテッド コロニー形成培地及びその使用
EP3450548A4 (en) 2016-04-27 2019-11-20 Rohto Pharmaceutical Co., Ltd. MESCHYMAL STEM CELL FOR EXPRESSING AT LEAST ONE CELL SURFACE MARKER SELECTED FROM THE GROUP OF CD201, CD46, CD56, CD147 AND CD165, AND METHOD FOR THE MANUFACTURE THEREOF AND PHARMACEUTICAL COMPOSITION WITH THE MESENCHYMAL STEM CELL AND METHOD FOR THE PRODUCTION THEREOF
KR101816246B1 (ko) 2016-09-07 2018-01-08 에스씨엠생명과학 주식회사 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물
CA3042031A1 (en) 2016-10-27 2018-05-03 The Trustees Of Columbia University In The City Of New York Immunosuppressive mesenchymal cells and methods for forming same
EP3551748B1 (en) 2016-12-12 2022-07-13 Health and Biotech France (H&B France) Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof
CN110494556B (zh) 2017-04-03 2024-04-30 株式会社钟化 包含间充质系干细胞的细胞群、其制造方法、以及医药组合物
WO2018186419A1 (ja) 2017-04-03 2018-10-11 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
JP7398959B2 (ja) 2017-05-04 2023-12-15 メゾブラスト・インターナショナル・エスアーエールエル 向上した免疫抑制作用を有する間葉系前駆または幹細胞

Also Published As

Publication number Publication date
EP2785359B1 (en) 2018-08-29
JP2018027954A (ja) 2018-02-22
JP7777430B2 (ja) 2025-11-28
AU2017239526A1 (en) 2017-10-26
KR20140127209A (ko) 2014-11-03
US20170252374A1 (en) 2017-09-07
TW202344258A (zh) 2023-11-16
JP6526130B2 (ja) 2019-06-05
KR102108245B1 (ko) 2020-05-08
CN104136034B (zh) 2018-04-24
US20210182552A1 (en) 2021-06-17
KR102811933B1 (ko) 2025-05-23
LT2785359T (lt) 2018-11-12
EP2785359A1 (en) 2014-10-08
CY1122275T1 (el) 2020-07-31
TWI698242B (zh) 2020-07-11
US20130183272A1 (en) 2013-07-18
US20250090590A1 (en) 2025-03-20
JP2019142958A (ja) 2019-08-29
KR20210044904A (ko) 2021-04-23
TW201331365A (zh) 2013-08-01
KR20230059838A (ko) 2023-05-03
TW201815399A (zh) 2018-05-01
AU2022202639B2 (en) 2025-06-12
JP2022027796A (ja) 2022-02-14
CA2857545A1 (en) 2013-06-06
US12097223B2 (en) 2024-09-24
AU2019264631A1 (en) 2019-12-05
JP2024067032A (ja) 2024-05-16
ES2690212T3 (es) 2018-11-19
SI2785359T1 (sl) 2018-11-30
US20160038543A1 (en) 2016-02-11
AU2017239526B2 (en) 2019-08-15
TW202537630A (zh) 2025-10-01
KR102246369B1 (ko) 2021-04-29
AU2019264631B2 (en) 2022-01-20
TWI698527B (zh) 2020-07-11
CN108478599A (zh) 2018-09-04
RS57886B1 (sr) 2019-01-31
PT2785359T (pt) 2018-11-06
US8962321B2 (en) 2015-02-24
TWI812867B (zh) 2023-08-21
WO2013082543A1 (en) 2013-06-06
EP2785359A4 (en) 2015-11-11
HRP20181515T1 (hr) 2018-11-16
HK1202798A1 (en) 2015-10-09
KR20200051827A (ko) 2020-05-13
TW202037373A (zh) 2020-10-16
CN104136034A (zh) 2014-11-05
DK2785359T3 (en) 2018-10-29
CN108478599B (zh) 2022-08-02
AU2012345630A1 (en) 2014-07-17
AU2022202639A1 (en) 2022-05-12
KR102525175B1 (ko) 2023-04-21
JP2015500810A (ja) 2015-01-08
EP3449929B1 (en) 2025-11-19
HUE040566T2 (hu) 2019-03-28
EP3449929A1 (en) 2019-03-06
JP6983195B2 (ja) 2021-12-17

Similar Documents

Publication Publication Date Title
PL2785359T3 (pl) Mezenchymalne komórki zrębowe i związane z nimi zastosowania
DK2837680T3 (da) Mammaliacellekultur
DK2775557T3 (da) Brændselscelle
EP2664017A4 (en) STACK OF FLOW CELLS
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
DK3442233T3 (da) Nedarvning i samplearraymultitræsunderinddeling
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
HRP20181152T1 (hr) Progenitorne stanice mezodermalnog porijekla
EP2557610A4 (en) Cell module
EP3719852C0 (en) SOLAR CELL
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
DK2683643T3 (da) Prostatacancercellelinjer, gensignaturer og anvendelser deraf
EP2535261A4 (en) SCHAUFELRADJACHT
BR112013007852A2 (pt) pilha reforçada aperfeiçoada
DK2912165T3 (da) Nyrecellepopulationer og anvendelser deraf
EP3701800C0 (en) Use
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
IL235125A0 (en) Microbial fuel cell
EP2626910A4 (en) PHOTOVOLTAIC CELL
EP2610945A4 (en) STACK CELL
EP2654170A4 (en) CHARGER
EP2831949A4 (en) SODIUM OXYGEN CELLS
DK2753346T3 (da) Ceramidase og celledifferentiering
EP2544283A4 (en) Fuel cell